Researchers Meet Behind Closed Doors for Routine NIH Review
Published Date: 11/10/2026
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a closed meeting on April 14, 2027, to review and evaluate the skills and performance of its researchers. This meeting affects scientists working on arthritis and related diseases and helps ensure top-quality research continues. The meeting will be both in person and virtual, with no direct money changes announced.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22550, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding two closed virtual meetings on November 30, 2026, to review important grant applications. These meetings affect researchers applying for funding in cardiovascular sciences and tobacco regulatory science. No public access is allowed to protect private info and trade secrets, and the reviews help decide who gets research money.
2026-22558, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early December 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for health-related projects, ensuring privacy for sensitive information. No direct money changes are announced, but these reviews help decide who gets research grants.
2026-22339, Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human
The National Institutes of Health plans to give AntaraCore Systems, Inc. an exclusive license to use new catheter technology that treats dangerous heart rhythm problems called ventricular arrhythmia. This means AntaraCore will have special rights to develop and sell this life-saving treatment. If you want to comment or apply for a license, you must do so by December 2, 2026.
2026-22196, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a public meeting on May 12, 2027, to discuss important council business and review grant applications. People interested can attend in person or online, but space is limited and some parts of the meeting will be private to protect sensitive information. This meeting affects researchers and organizations seeking funding and sets the stage for future diabetes and kidney disease research support.
2026-22111, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 4, 2027, to share updates and review grant applications and staff performance. The first half is open to the public, while the second half is private to protect personal privacy. This meeting affects researchers and staff involved with NICHD grants and projects, with no direct cost changes announced.
2026-22114, Fogarty International Center; Notice of Meeting
The Fogarty International Center Advisory Board is meeting on June 7, 2027, both in-person and online to share updates and review important grant applications. This meeting affects researchers and organizations applying for funding, with some sessions open to the public and others closed to protect privacy and trade secrets. No registration is needed to join the open session, making it easy to stay informed about global health research funding.
Previous / Next Documents
Previous: 2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
Next: 2026-22845, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend IEX Rule 3.291 (Influencing or Rewarding Employees of Others; Gratuities), To Conform to the Rules of FINRA for Purposes of an Agreement Between the Exchange and FINRA Pursuant To Rule 17d-2 Under the Act
Investors Exchange LLC (IEX) is updating its rule about giving gifts or rewards to employees of other companies to match the Financial Industry Regulatory Authority’s (FINRA) rules. This change helps IEX and FINRA work together smoothly under a special agreement. The new rule is effective immediately and doesn’t affect any fees or costs for anyone involved.